CLAIMS

1. A compound of formula (I)


A^1-X^1-X^2-A^2 (I)

wherein:


A^2 is a paclitaxel moiety; and

-X^2-X^1-A^1 is –(C(=O)-$(CH_2)_{n1}$-C(=O)-OH, wherein n1 is an integer from 12 to 24; or –X^2-X^1-A^1 is –C(=O)-$(CH_2)_7$-CH=CH-$(CH_2)_7$-C(=O)-OH.

2. The compound of claim 1, wherein the paclitaxel moiety is a moiety of the formula:



3. The compound of claim 1, which is a compound of the formula:



or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising: a compound of claim 1; and a protein, wherein the protein is human serum albumin or a protein whose sequence is at least 50% equivalent to that of human serum albumin.

5. The pharmaceutical composition of claim 4, wherein the protein is human serum albumin.

6. The pharmaceutical composition of claim 4, further comprising a carrier.

7. The pharmaceutical composition of claim 6, wherein the carrier comprises water.

8. The compound of claim 2, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{n1}-C(=O)-OH$, wherein n1 is an integer from 12 to 24.

9. The compound of claim 1, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{14}-C(=O)-OH$.

10. The compound of claim 1, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{16}-C(=O)-OH$.

11. The compound of claim 1, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{18}-C(=O)-OH$.


12. The compound of claim 1, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_7-CH=CH-(CH_2)_7-C(=O)-OH$.

13. The compound of claim 2, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{14}-C(=O)-OH$.

14. The compound of claim 2, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_{18}-C(=O)-OH$.

15. The compound of claim 2, wherein $-X^2-X^1-A^1$ is $-C(=O)-(CH_2)_7-CH=CH-(CH_2)_7-C(=O)-OH$.

16. The compound of claim 1, which is a compound of the formula:



17. A pharmaceutical composition comprising:

a compound of claim 3; and

a protein, wherein the protein is human serum albumin or a protein whose sequence is at least 50% equivalent to that of human serum albumin.

18. A pharmaceutical composition comprising:

a compound of claim 16; and

a protein, wherein the protein is human serum albumin or a protein whose sequence is at least 50% equivalent to that of human serum albumin.

19. Use of a composition of any one of claim 4, claim 17 or claim 18 in the manufacture of a medicament for the treatment of cancer.